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OBJECTIVES: To assess the cost-effectiveness of Rebif com-
pared to its comparators in the German health care setting in
2008. METHODS: A decision analysis model was used to esti-
mate the cost-effectiveness of Rebif in patients with relapsing-
remitting multiple sclerosis (RRMS). The analysis was based on
a comparison of treatment with Rebif (44 mcg tiw) versus all
other existing disease modifying drug (DMD) treatments from a
societal perspective: Avonex (30 mcg qw), Betaferon (8 MIU
qod), Copaxone (20 mg qd). Data sources used included pub-
lished literature, clinical trials, ofﬁcial German price/tariff lists
and national population statistics. The time horizon of the
model was four years, which is the maximum follow-up of
patients in published clinical trials with interferons. RESULTS:
The cost-effectiveness expressed in cost per relapse avoided is
€51,250 for Rebif, which compares favourably with the other
comparators. The cost per relapse avoided is €133,770 for
Avonex, €71,416 for Copaxone and €54,475 for Betaferon,
respectively. When cost of disease progression is excluded, the
cost per relapse avoided remains favourable for Rebif (€ 54,292)
compared with the other drugs (Avonex €143,186, Copax-
one €72,809, Betaferon €56,816). Sensitivity analyses varying
the discount rate, frequency of type of relapse, cost of relapse,
cost of disease progression and non-compliance have a minor
impact on the study outcomes. CONCLUSIONS: This study
provides evidence on the cost-effectiveness of ﬁrst-line treatment
options for multiple sclerosis in the German setting. In particu-
lar, we found that the cost-effectiveness associated with Rebif 44
was favourable compared to other DMDs, providing additional
value to payers.
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OBJECTIVES: To investigate the cost-effectiveness of aripipra-
zole compared to standard-of-care (SOC) in the Schizophrenia
Trial of Aripiprazole (STAR). METHODS: STAR was a multi-
centre, 26-week, randomised, naturalistic, open-label study com-
paring aripiprazole with SOC (deﬁned as clinician’s choice of
olanzapine, quetiapine or risperidone) in the management of
community-treated patients with schizophrenia (1). The primary
outcome in the cost-effectiveness analysis was the cost per unit of
improvement on the main clinical outcome in STAR, the Inves-
tigator’s Assessment Questionnaire (IAQ) (2). Secondary
outcome measures were the cost per additional CGI-I responder
and the cost per unit of improvement on the Quality of Life Scale
(QLS). Data on service use and employment were collected
alongside the trial. Statistical adjustment was made for baseline
characteristics on all outcomes. The perspective taken was that of
the NHS and social care in the UK. RESULTS: Aripiprazole was
associated with a signiﬁcantly better improvement on the IAQ
(p = 0.0002), the CGI-I response rate (p = 0.0080) and the QLS
scores (p = 0.0003) as compared to SOC. The improvement
observed in the QLS scores at six months in this study
approached that of clinical signiﬁcance at 1 year (3.4). The
incremental cost effectiveness ratio (ICER) for the IAQ was £714
per unit of improvement. We estimated that a clinically signiﬁ-
cant improvement would be an 8 point improvement in the IAQ
score. The cost per 1% increase in the number of CGI-I respond-
ers was £1413. Thus it would cost £1413 to go from 10 to 11
responders in a sample of 100 patients. The ICER for the QLS
suggests a cost of £288 for each unit of improvement gained.
CONCLUSIONS: Aripiprazole has shown to provide improve-
ments in effectiveness and quality of life at a reasonable cost
compared to SOC based on an economic analysis of a naturalistic
trial.
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OBJECTIVES: To assess the economic burden of moderate
Alzheimer’s Disease (AD) and to analyze the impact of depres-
sion, from the societal perspective. METHODS: IDEAL is an
epidemiological, prospective and multicentric study in which
1,071 patients from 180 investigators in Spain, with moderate
AD and available information on resources were assessed.
Resources consumption was assessed in a cross-sectional way at
the end of the study. The following resources were included in the
analysis: health care (medication: anti-Alzheimer, neuroleptics
and anti-depressive drugs) and non-health care direct costs
(formal care and social services: institutionalization and day care
center attendance) and indirect costs (caregivers loss of produc-
tivity). Costs are expressed in euros 2007. The cognitive and
functional status were measured by the Mini-Mental State
Examination (MMSE) and Barthel Index, respectively. Patients
were grouped taking into account the score obtained in the
depression Cornell Scale (cut-off-point: 8). RESULTS: Depres-
sion was present in 52% of the patients. The average monthly
cost per patient was €1043 and €653 in patients with and
without depression, respectively. Non-health care direct costs
and the caregivers loss of productivity were the most important
cost categories. In patients with depression, 56%, 34% and 10%
were attributable to non-health care direct costs, productivity
loss and drug costs, respectively. In comparison, in patients
without depression, the same distribution costs were 61%, 25%
and 14%. The cost of productivity loss is more than doubled in
the depression patient cohort. Patients with depression showed a
higher and signiﬁcant cognitive impairment, through MMSE
scores: 14.7 (4.7) in depressed patients and 15.2 (4.9) in
non-depressed patients. The same ﬁnding was observed in the
daily life activities measured by the Barthel Index: 68.2 (22.7)
and 81.1 (19.9) in patients with and withour depression. CON-
CLUSIONS: Adequate management of depression in patients
with moderate AD would have a positive impact on societal
resource consumption.
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OBJECTIVES: Compare annual direct costs (both total and
epilepsy-related) between privately insured U.S. epilepsy patients
and matched controls. METHODS: A total of 4323 patients with
greater than or equal to 1 epilepsy diagnosis (ICD-9-CM: 345.x),
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